We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Research Institutes Partner to Develop a Global Center for Transformative Nanomedicine

By LabMedica International staff writers
Posted on 25 Oct 2015
Print article
Two internationally renowned biomedical research institutions have agreed to collaborate in the establishment of a virtual center to boost development of nanotechnological techniques for diagnosis and treatment of disease.

The Hebrew University of Jerusalem (Israel) and the Cleveland Clinic (OH, USA) announced a five-year commitment to raise at least 15 million USD as initial funding to establish the virtual Center for Transformative Nanomedicine. This center will sponsor interdisciplinary research at the Hebrew University in combination with the Cleveland Clinic’s Department of Biomedical Engineering with the goal of developing nanotechniques that will facilitate therapy and new ways of diagnosing diseases.

Research efforts will encompass a wide range of illnesses including cardiovascular diseases, neurological diseases, and cancer. Investigators involved in the program will endeavor to develop nanomethods for drug transport that will allow delivery of large doses of drugs to be released at a specific site and only to that site, causing fewer side effects than traditional treatments. In addition, they plan to develop inexpensive nanoscale devices to facilitate therapy and diagnosis.

“Our two institutions will leverage resources and begin to combine our scientific knowledge,” said Dr. Menahem Ben-Sasson, president of The Hebrew University of Jerusalem. “These powerful interactions will expedite better medical treatments, more rapid, cost-effective diagnostics, and improved healthcare delivery for people the world over.”

“We are honored to join with Hebrew University to advance the emerging field of nanotechnology,” said Dr. Toby Cosgrove, president and CEO of the Cleveland Clinic. “The new Center for Transformative Nanomedicine will ensure development of novel therapeutics to improve longevity, enhance patient well-being, make medical care more cost-effective, and provide dynamic solutions to global health concerns.”

The initial development stage will be directed by Dr. D. Geoffrey Vince, of the Cleveland Clinic and Dr. Simon Benita of the Hebrew University of Jerusalem.

Related Links:

The Hebrew University of Jerusalem
Cleveland Clinic


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.